Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2006 for Phase III Medical, Inc. (formerly Lisata Therapeutics, Inc.). On January 19, 2006, the Company acquired the assets of NeoStem, Inc., shifting its principal business to the collection, processing, and storage of adult stem cells. The Company is currently in a "run-off" phase for its legacy extended warranty business, which is expected to cease generating revenue within seven months. Management has expressed substantial doubt regarding the Company's ability to continue as a going concern due to limited financial resources and a history of losses.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2006 | Six Months Ended June 30, 2005 |
|---|---|---|
| Revenue | $12,524 | $19,983 |
| Gross Profit | $3,590 | $5,963 |
| Operating Loss | $(1,974,644) | $(568,298) |
| Net Loss | $(2,384,526) | $(642,736) |
| Cash and Cash Equivalents (End of Period) | $912,250 | $260 |
| Net Cash Used in Operating Activities | $(1,783,626) | $(332,608) |
| Net Cash Provided by Financing Activities | $2,207,004 | $305,000 |
| Total Current Liabilities | $2,662,533 | $1,752,403 |
| Working Capital Deficit | $(1,631,050) | $(1,245,084) |
Note: Revenue is derived entirely from the legacy warranty business; the new stem cell business has not yet generated revenue.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by approximately 37% year-over-year as the legacy warranty business enters its final run-off phase.
- Significant Increase in Expenses: Selling, general, and administrative (SG&A) expenses surged by approximately $1.4 million for the six-month period. This increase is attributed to the NeoStem acquisition, including new payroll, legal fees, and a $386,500 signing bonus/compensation package for new CEO Dr. Robin Smith.
- Interest Expense Spike: Interest expense increased by approximately $338,000, driven by the amortization of debt discounts and the fair value of warrants associated with convertible notes issued in late 2005 and early 2006.
- Liquidity Improvement: Cash balances increased from $260 to $912,250, primarily due to a $2.08 million private placement of common stock and warrants in June 2006.
- Debt Structure: The Company converted all Series A Preferred Stock into common stock in March 2006, eliminating the associated dividend obligation.
Outlook, Risks, and Unusual Items
- Going Concern Warning: The Company's financial statements include a "substantial doubt" disclosure regarding its ability to continue as a going concern. Substantial additional financing is required to fund operations.
- Financing Activities: The Company successfully raised approximately $2.08 million in June 2006 via the "Duncan Private Placement." Subsequent to the reporting period, an additional $300,000 was raised in July and August 2006.
- Convertible Note Penalties: The Company failed to file a required registration statement by July 31, 2006, triggering penalty clauses on convertible notes (reduction of conversion prices). The Company has negotiated extensions and conversion options with investors to mitigate these penalties.
- Regulatory Risks: The Company faces significant regulatory hurdles regarding FDA registration and state licensing for stem cell banking. Failure to comply could result in injunctions or fines.
- Market Acceptance: Future profitability depends entirely on the commercialization of stem cell services, which requires significant marketing spend and physician acceptance.
Investor Verification Checklist
- Cash Runway: Verify if the $912,250 cash balance is sufficient to cover the current monthly burn rate given the high operating losses.
- Debt Conversion Terms: Confirm the final terms of the convertible note extensions and conversions negotiated with Westpark investors to assess potential dilution.
- Revenue Timeline: Assess the realistic timeline for the NeoStem business to generate its first dollar of revenue, as the legacy business is expiring.
- Regulatory Status: Verify the status of the California biologics license and any pending applications in other states required for expansion.
- Stock Dilution: Review the impact of the 151+ million shares outstanding plus 28.75 million options and 33.5 million warrants on future equity value.